Categories AlphaGraphs, Earnings, LATEST, Technology

iRobot’s stock tumbles after Q2 revenues miss estimates

iRobot (NASDAQ: IRBT) topped earnings estimates for the second quarter of 2019 but revenues missed expectations, sending the stock crashing 15.9% in after-market hours on Tuesday.

Total revenue of $260.2 million rose 15% year-over-year, driven by double-digit expansion in all major geographic regions, but fell short of consensus estimates of $267.9 million.

iRobot reports second quarter 2019 earnings results

Net income was $7.2 million, or $0.25 per share, compared to $10.4 million, or $0.37 per share, in the year-ago quarter. Adjusted EPS totaled $0.48. Analysts had forecasted earnings of $0.03 per share.

In the second quarter, revenues grew 12% in the US and 18% internationally. The company also launched the Roomba s9 vacuum and Braava jet m6 mop during the period.

Colin Angle, CEO of iRobot said, “The successful launch of our new Roomba s9 vacuums and Braava jet m6 mops at the end of May represented an important milestone in our plans to strengthen Roomba leadership, extend the portfolio beyond vacuuming and advance our position in the Smart Home.”

iRobot expects the impacts of the US-China trade war and the recently implemented 25% tariffs to constrain its US market segment growth in the second half of the year. Based on the year-to-date performance and the impact of tariffs on domestic segment growth, the company revised its guidance for the full year of 2019.

iRobot now expects revenues to grow approx. 10-14% year-over-year to a range of $1.2-1.25 billion.  This compares to the previous range of $1.28-1.31 billion. EPS is expected to be $2.40-3.15 versus the prior outlook of $3.15-3.40.  

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top